Hepatitis C News and Research

Latest Hepatitis C News and Research

Novartis to acquire 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical for US$125 million

Hard To Treat Diseases (HTDS.PK) www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million.

10 Nov 2009

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

NanoViricides to present data on its in vivo studies against influenza

NanoViricides, Inc., announced today that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment.

9 Nov 2009

Third-quarter 2009 financial results announced by Inhibitex

Inhibitex, Inc., today announced its financial results for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 million at December 31, 2008.

6 Nov 2009

Grant awarded for research into a new treatment for methamphetamine addiction

Dr. Keith Flower - a research physician at the Addiction Pharmacology & Research Laboratory in San Francisco, CA - has been awarded a grant to investigate a new medication treatment for methamphetamine addiction. This grant has been awarded to California Pacific Medical Center's Research Institute through President Obama's AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009.

6 Nov 2009

Walls Street journal examines big pharma's 'growing interest' in emerging-market vaccine development, production

The Wall Street Journal examines "big pharma's growing interest in a corner of healthcare - emerging-market inoculations," in light of a recent move by Novartis to purchase an 85 percent stake in the Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical Co. In the summer, drug maker Sanofi-Aventis SA made a similar move to acquire a majority stake in India's Shantha Biotechnics, the newspaper notes.

6 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Mandatory minimum sentences for drug-related offences, an ineffective approach

Mandatory minimum sentences for drug-related offences are an expensive and ineffective approach to substance use problems in Canada. That's the message being delivered today by an addictions professional at Canada's largest mental health and addictions treatment and research hospital to a Senate Committee on Bill C-15 - legislation that would create mandatory minimum sentences for certain drug-related offences.

5 Nov 2009

InterMune seeks FDA marketing approval for pirfenidone

InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.

5 Nov 2009

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $208 million to two programs that support research to better understand the human immune response to emerging and re-emerging infectious diseases, including those that may be introduced into a community through acts of bioterrorism.

5 Nov 2009

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.

5 Nov 2009

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.

4 Nov 2009

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected. In this clinical trial to be presented at the annual meeting of the American Association for the Study of Liver Diseases, researchers treated patients - both treatment naive and experienced patients - with a twice daily oral combination therapy of a nucleoside polymerase and protease inhibitor.

4 Nov 2009

Stress-reduction workshops for women with history of breast cancer

Are you stressed? Do you have a family history of breast cancer? Health SMART is a study is being conducted by researchers at Fred Hutchinson Cancer Research Center to see how stress-reduction workshops can help women with a family history of breast cancer manage their everyday stresses and cancer-risk concerns.

4 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

WHO, UNICEF launch 6-year $39B plan to prevent, treat pneumonia; World Pneumonia Day coverage

To mark the first World Pneumonia Day on Monday, the WHO and UNICEF launched a $39 billion Global Action Plan for Prevention and Control of Pneumonia (GAPP) aimed at preventing 5.3 million child deaths from the disease by 2015, the Associated Press reports (Cheng, 11/1).

3 Nov 2009

Sanofi Pasteur presents Menactra vaccine safety data at the IDSA

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, presented Safety of a Quadrivalent (A,C,Y,W-135) Meningococcal Vaccine When Given to Infants with Other Pediatric Vaccines at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) this past weekend.

2 Nov 2009

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.

2 Nov 2009

Canadian programs underscore evidence of PEGETRON's positive outcomes in treating HCV infection

Results from two significant Canadian studies underscore the growing scientific evidence of PEGETRON's positive outcomes in the treatment of chronic hepatitis C virus (HCV) infection. Canadian investigators across the country collaborated to generate and analyze clinical data from the Canadian PEGETRON POWeR (Prospective Optimal Weight-based Dosing Response) and REDIPEN programs, which were presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston on November 1, 2009.

2 Nov 2009

Methacetin breath test predicts long-term survival in patients with chronic viral hepatitis

A methacetin breath test (MBT) that can be performed quickly and noninvasively has been proven to accurately predict survival in patients with viral hepatitis and may be used as an adjunctive tool to MELD.

2 Nov 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

Novartis to acquire 85% stake in Zhejiang Tianyuan Bio-Pharmaceutical for US$125 million

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

NanoViricides to present data on its in vivo studies against influenza

Third-quarter 2009 financial results announced by Inhibitex

Grant awarded for research into a new treatment for methamphetamine addiction

Walls Street journal examines big pharma's 'growing interest' in emerging-market vaccine development, production

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Mandatory minimum sentences for drug-related offences, an ineffective approach

InterMune seeks FDA marketing approval for pirfenidone

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

Stress-reduction workshops for women with history of breast cancer

Interim data from Schering-Plough's narlaprevir Phase IIa study

WHO, UNICEF launch 6-year $39B plan to prevent, treat pneumonia; World Pneumonia Day coverage

Sanofi Pasteur presents Menactra vaccine safety data at the IDSA

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Canadian programs underscore evidence of PEGETRON's positive outcomes in treating HCV infection

Methacetin breath test predicts long-term survival in patients with chronic viral hepatitis

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in